We further demonstrated that diastolic dysfunction and cardiac hypertrophy could be prevented in HFpEF mice by administration of recombinant ANGPTL4, which was also associated with reduced collagen IV deposition. This evidence concerns the gene ANGPTL4 and cardiac hypertrophy.